Adjuvant chemotherapy enhances long‐term survival of patients with advanced gastric cancer following curative resection

Yoshihiko Maehara, Sunao Moriguchi, Yoshihisa Sakaguchi, Yasunori Emi, Shunji Kohnoe, Shunichi Tsujitani, Keizo Sugimachi

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

We examined the effectiveness of postoperative adjuvant chemotherapy with mitomycin C (MMC), 1‐(2‐tetrahydrofuryl)‐5‐fluorouracil (tegafur), plus PSK, an immunomodulator, for patients with advanced gastric cancer who underwent histological curative resection. The effect of chemotherapy on prognostic serosal (ps) invasion [ps(−) or ps(+)] and lymph node metastasis [n(−) or n(+)] was examined. One hundred eighteen patients were in the no‐chemotherapy group and 137 were on the drugs. The median follow‐up time for the 86 survivors at the time of analysis was 13.8 years. With regard to prognostic factors, there were no differences between the two groups. Generalized Wilcoxon test of the two survival patterns revealed a P value of .0351, and the survival rate for 15 years was 45.7% for patients in the no‐chemotherapy group and 56.9% for those of the chemotherapy group. In particular, adjuvant chemotherapy was effective for patients with ps(−)n(+) (P <.05) and ps(+)n(−) ( P <.05), but not for those with ps(−)n(−) and ps(+)n(+). Our findings show that the concomitant prescription of MMC, tegafur, and PSK improves the 15‐year survival rate for patients with advanced gastric cancer, following curative resection. As the survival rate is low for the patients with ps(+)n(+), an even more aggressive postoperative chemotherapy is recommended.

Original languageEnglish
Pages (from-to)169-172
Number of pages4
JournalJournal of Surgical Oncology
Volume45
Issue number3
DOIs
Publication statusPublished - Jan 1 1990

Fingerprint

Adjuvant Chemotherapy
Stomach Neoplasms
Survival
Tegafur
Survival Rate
Mitomycin
Drug Therapy
Immunologic Factors
Prescriptions
Survivors
Lymph Nodes
Neoplasm Metastasis
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Surgery
  • Oncology

Cite this

Adjuvant chemotherapy enhances long‐term survival of patients with advanced gastric cancer following curative resection. / Maehara, Yoshihiko; Moriguchi, Sunao; Sakaguchi, Yoshihisa; Emi, Yasunori; Kohnoe, Shunji; Tsujitani, Shunichi; Sugimachi, Keizo.

In: Journal of Surgical Oncology, Vol. 45, No. 3, 01.01.1990, p. 169-172.

Research output: Contribution to journalArticle

Maehara, Y, Moriguchi, S, Sakaguchi, Y, Emi, Y, Kohnoe, S, Tsujitani, S & Sugimachi, K 1990, 'Adjuvant chemotherapy enhances long‐term survival of patients with advanced gastric cancer following curative resection', Journal of Surgical Oncology, vol. 45, no. 3, pp. 169-172. https://doi.org/10.1002/jso.2930450307
Maehara, Yoshihiko ; Moriguchi, Sunao ; Sakaguchi, Yoshihisa ; Emi, Yasunori ; Kohnoe, Shunji ; Tsujitani, Shunichi ; Sugimachi, Keizo. / Adjuvant chemotherapy enhances long‐term survival of patients with advanced gastric cancer following curative resection. In: Journal of Surgical Oncology. 1990 ; Vol. 45, No. 3. pp. 169-172.
@article{f297d85042794f818b968a31308b104b,
title = "Adjuvant chemotherapy enhances long‐term survival of patients with advanced gastric cancer following curative resection",
abstract = "We examined the effectiveness of postoperative adjuvant chemotherapy with mitomycin C (MMC), 1‐(2‐tetrahydrofuryl)‐5‐fluorouracil (tegafur), plus PSK, an immunomodulator, for patients with advanced gastric cancer who underwent histological curative resection. The effect of chemotherapy on prognostic serosal (ps) invasion [ps(−) or ps(+)] and lymph node metastasis [n(−) or n(+)] was examined. One hundred eighteen patients were in the no‐chemotherapy group and 137 were on the drugs. The median follow‐up time for the 86 survivors at the time of analysis was 13.8 years. With regard to prognostic factors, there were no differences between the two groups. Generalized Wilcoxon test of the two survival patterns revealed a P value of .0351, and the survival rate for 15 years was 45.7{\%} for patients in the no‐chemotherapy group and 56.9{\%} for those of the chemotherapy group. In particular, adjuvant chemotherapy was effective for patients with ps(−)n(+) (P <.05) and ps(+)n(−) ( P <.05), but not for those with ps(−)n(−) and ps(+)n(+). Our findings show that the concomitant prescription of MMC, tegafur, and PSK improves the 15‐year survival rate for patients with advanced gastric cancer, following curative resection. As the survival rate is low for the patients with ps(+)n(+), an even more aggressive postoperative chemotherapy is recommended.",
author = "Yoshihiko Maehara and Sunao Moriguchi and Yoshihisa Sakaguchi and Yasunori Emi and Shunji Kohnoe and Shunichi Tsujitani and Keizo Sugimachi",
year = "1990",
month = "1",
day = "1",
doi = "10.1002/jso.2930450307",
language = "English",
volume = "45",
pages = "169--172",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Adjuvant chemotherapy enhances long‐term survival of patients with advanced gastric cancer following curative resection

AU - Maehara, Yoshihiko

AU - Moriguchi, Sunao

AU - Sakaguchi, Yoshihisa

AU - Emi, Yasunori

AU - Kohnoe, Shunji

AU - Tsujitani, Shunichi

AU - Sugimachi, Keizo

PY - 1990/1/1

Y1 - 1990/1/1

N2 - We examined the effectiveness of postoperative adjuvant chemotherapy with mitomycin C (MMC), 1‐(2‐tetrahydrofuryl)‐5‐fluorouracil (tegafur), plus PSK, an immunomodulator, for patients with advanced gastric cancer who underwent histological curative resection. The effect of chemotherapy on prognostic serosal (ps) invasion [ps(−) or ps(+)] and lymph node metastasis [n(−) or n(+)] was examined. One hundred eighteen patients were in the no‐chemotherapy group and 137 were on the drugs. The median follow‐up time for the 86 survivors at the time of analysis was 13.8 years. With regard to prognostic factors, there were no differences between the two groups. Generalized Wilcoxon test of the two survival patterns revealed a P value of .0351, and the survival rate for 15 years was 45.7% for patients in the no‐chemotherapy group and 56.9% for those of the chemotherapy group. In particular, adjuvant chemotherapy was effective for patients with ps(−)n(+) (P <.05) and ps(+)n(−) ( P <.05), but not for those with ps(−)n(−) and ps(+)n(+). Our findings show that the concomitant prescription of MMC, tegafur, and PSK improves the 15‐year survival rate for patients with advanced gastric cancer, following curative resection. As the survival rate is low for the patients with ps(+)n(+), an even more aggressive postoperative chemotherapy is recommended.

AB - We examined the effectiveness of postoperative adjuvant chemotherapy with mitomycin C (MMC), 1‐(2‐tetrahydrofuryl)‐5‐fluorouracil (tegafur), plus PSK, an immunomodulator, for patients with advanced gastric cancer who underwent histological curative resection. The effect of chemotherapy on prognostic serosal (ps) invasion [ps(−) or ps(+)] and lymph node metastasis [n(−) or n(+)] was examined. One hundred eighteen patients were in the no‐chemotherapy group and 137 were on the drugs. The median follow‐up time for the 86 survivors at the time of analysis was 13.8 years. With regard to prognostic factors, there were no differences between the two groups. Generalized Wilcoxon test of the two survival patterns revealed a P value of .0351, and the survival rate for 15 years was 45.7% for patients in the no‐chemotherapy group and 56.9% for those of the chemotherapy group. In particular, adjuvant chemotherapy was effective for patients with ps(−)n(+) (P <.05) and ps(+)n(−) ( P <.05), but not for those with ps(−)n(−) and ps(+)n(+). Our findings show that the concomitant prescription of MMC, tegafur, and PSK improves the 15‐year survival rate for patients with advanced gastric cancer, following curative resection. As the survival rate is low for the patients with ps(+)n(+), an even more aggressive postoperative chemotherapy is recommended.

UR - http://www.scopus.com/inward/record.url?scp=0025175858&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025175858&partnerID=8YFLogxK

U2 - 10.1002/jso.2930450307

DO - 10.1002/jso.2930450307

M3 - Article

C2 - 2122131

AN - SCOPUS:0025175858

VL - 45

SP - 169

EP - 172

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 3

ER -